Non-Small Cell Lung Cancer Therapeutics Market Expected to Reach US$ 15.1 Bn in 2023

Non-Small Cell Lung Cancer Therapeutics Market: Snapshot

Non-small cell lung cancer (NSCLC) is the one of the commonest form of lung cancers. It is the most feared too. This is because it metastasizes into the bones and other tissues, making it tough to diagnose and treat it. In fact, almost 90% of all lung cancer cases are non-small cell lung cancer. Drugs meant to treat such a type of cancer range from regular regimens to targeted therapies. They are formulated leveraging simple chemistries to advanced complex proteins. The global market for non-small cell lung cancer therapeutics has seen robust growth due to the strong awareness among people about it. Another factor majorly contributing to the market is favorable government initiatives. Further, rapid approvals for drugs for non-small cell lung cancer by regulatory bodies and generous monetary assistance for research has also filliped the market.

Despite the efficacy of targeted therapies and the uncovering of numerous molecular targets, the development of most drugs is in an early-stage pipeline. This, coupled with resistance to targeted therapies, is a major cause of worry in the non-small cell lung cancer therapeutics market.

Read Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

The global non-small cell lung cancer therapeutics market was worth US$4.9 bn in 2014. Expanding at a CAGR of 12.1% from 2015 to 2023, it is slated to achieve a value of US$15.1 bn in 2023. The global non-small cell lung cancer therapeutics market is a fragmented with robust competition among the existing players that are both generic and branded companies. Some of the prominent names operating in the market are Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc., AstraZeneca plc, and Novartis AG.

Burgeoning Population to Propel Market in Asia Pacific

The global market for non-small cell lung cancer therapeutics comprises five key regions: North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America leads with maximum share in market on account of the presence of a superior healthcare infrastructure and strong support by the U.S. federal government. In terms of growth rate, however, Asia Pacific is predicted to outshine all other regions owing to the burgeoning population, growing awareness about non-small cell lung cancer, increasing number of government projects pertaining to lung cancer, and ongoing efforts for timely intervention.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Effectiveness of Angiogenesis Inhibitor Drives Growth

The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.

The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.

Growing Prevalence of Lung Cancer Accelerates Global Non-small Cell Lung Cancer Market

Genentech, a Roche company, dominates the global non-small cell lung cancer (NSCLC) therapeutics market, individually accounting for more than 36% of the market shares in 2014. Transparency Market Research finds that the market is characterized by the presence of both generic and branded companies, and positions Eli Lilly and Company as the second-most prominent player. Rest of the market is fragmented, and highly competitive, with a few formidable players including AstraZeneca plc, Celgene Corporation, Bristol-Myers Squibb, Novartis AG, Pfizer, Inc., Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd.

Rated as the most dreaded of all types of lung cancer, new NSCLC drugs are readily given approval by regulatory bodies, and research and development is encouraged. This factor is leading to rapid innovation, which will eventually decide the leader of the market in future. The global market for non-small cell lung cancer therapeutics was valued at US$4.9 bn in 2014. Rising at a robust CAGR of 12.10% during the forecast period of 2015 to 2023, the valuation is estimated to reach a US$15.1 bn mark by the end of 2023.

Read Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

Zykadia Projected for Strongest Growth Rate

The global NSCLC market has been bifurcated on the basis of drugs class, pipeline stage, and geography. By drug class, the market is categorized into angiogenesis inhibitor, epidermal growth factor receptor (EGFR) blocker, kinase inhibitor, folate antimetabolites, microtubule stabilizer, and PD-1/PD-L1 inhibitors. In 2014, the segment of angiogenesis inhibitor dominated the demand, owing to reasons such as high efficacy, targeted therapies, and increasing demand from country-wide markets of the U.S. and Japan. The report rates Zykadia, a sub-segment of kinase inhibitor, for the strongest CAGR during the forecast period, followed by Opdivo, a sub-segment of PD-1/PD-L1 inhibitors.

Geographically, the report studies the regional non-small cell lung cancer therapeutics markets in North America, Europe, Asia Pacific, and Rest of the World. North America dominated the demand in 2014 due to the presence of robust healthcare infrastructure and an efficient government system in the U.S. and Canada. However, Asia Pacific is expected to boost the demand at a stronger CAGR during the forecast period due to vast population, growing awareness about NSCLC, and increased governmental projects related to lung, cancer, and tobacco.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Wide Patient Pool Augmenting Demand

In recent past, the demand for NSCLC therapeutics has surged significantly, and has become the most common type of lung cancer. According to American lung cancer society, about two out of three people diagnosed with lung cancer are 65 years or older. According to the author of the report, “This increasing pool of patients and rising geriatric population across the globe are the primary drivers in the global market for non-small cell lung cancer therapeutics.” Additionally, the author adds that approval of some of the late-stage pipeline products, such as necitumumab and onartuzumab will further fuel the growth rate in positive direction. The report also observes that drugs used in the NSCLC treatment range from regular regimens to targeted therapies, and concurrently are based on simple chemistries to advanced complex protein. As the awareness about the prevalence of lung cancer multiplies, several governments across the globe are offering favorable policies for the players in the market. This factor is also expected to fuel the demand during the forecast period.

The information presented in this review is based on a Transparency Market Research report, titled, “Non-small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

Microbiology Culture Market grows with rising demand for antibiotics and the increasing life science research funding

The intense rivalry between Merck Millipore, Thermo Fisher, Sigma-Aldrich, and Becton, Dickinson and Co. characterizes the competitive landscape of the global microbiology culture market, finds a research study by Transparency Market Research (TMR). In 2015, these four players held a share of nearly 53% in the overall market.

With leading participants focusing aggressively towards product innovation and reaching new breakthroughs, the competition within the market is likely to remain high over the next few years. These companies are looking to expand their bases to emerging economies, such as India, Brazil, and China, in order to exploit the untapped opportunities they hold.

According to the research study, the worldwide market for microbiology culture presented an opportunity worth US$4.51 bn in 2014. Progressing at a CAGR of 5.90% during the period from 2015 to 2023, the market is likely to reach US$7.59 bn by the end of the forecast period. Bacterial culture has gained prominence in the global market and is expected to retain it over the period of forecast, expanding at a CAGR of 6.70%.

Read Full Report: http://www.transparencymarketresearch.com/microbiology-culture-market.html

Significant Rise in Government Funding to Ensure North America’s Lead

The report also analyzes the global market for microbiology culture on its geographical presence. As per the study, Asia Pacific, North America, Europe, the Middle East, Latin America, and the Rest of the World are the main geographical sections of this market. With the significant rise in the government funding to increase research and development activities in microbiology, Europe and North America have emerged as the leading contributors to the global market. Researchers project North America to retain its position with a share of nearly 35% by the end of the forecast period.

On the similar line, Asia Pacific is also anticipated to witness strong growth over the forecast period, thanks to the rise in the disposable income of consumers, advancement in healthcare infrastructure, and the high prevalence of infectious diseases.

Growing usage of Antibiotics in Bacterial and Protozoan Infection Therapeutics to Boost Demand for Microbiology Culture

“The increasing demand for antibiotics is the key factor behind the rising the practice of microbiology culture,” states the author of this study. With the growing usage of antibiotics for the treatment of various bacterial and protozoan infections, the need for its large-scale production has increased substantially as the available quantity of naturally-occurring antibiotics is very less. As a result, microbes are being cultured under controlled conditions to raise their biomass and separate antibiotics from them, which eventually, is leading to a remarkable rise of the global microbiology culture market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3232

On the flip side, the high costs of culture media and the constant operation of fermentation vessel over a number of weeks may create obstacles to the growth of this market over the next few years. The difficult procedure of alternative nutrient source identification for the progression of various microorganisms in a bid to meet the exact requirements and the urgent need to decrease the cost of large-scale fermentation are also projected to limit microbial culture practices in the coming years, states the research report.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Microbiology Culture Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”

Global Demand for Spinal Muscular Atrophy Market 2023

Spinal Muscular Atrophy Market: Pipeline Analysis Snapshot

The number of people affected with spinal muscular atrophy is increasing globally. As stated in a publication by CureSMA, at least one in fifty people carry the defective spinal muscular atrophy gene. It should be noted that the research does not include the entire global population and therefore the total number and proportion of SMA gene carriers can be much higher than estimated. This is a key reason for the growth of research and development efforts put into understanding spinal muscular atrophy and discovering feasible treatments for it.

The market is, however, currently restrained by the overall lack of research in terms of the types of spinal muscular atrophy that exist. Research organizations and government bodies are constantly working to measure the growth of spinal muscular atrophy in concerned regions. However, they do not include the various types of spinal muscular atrophy in their research, thus creating a large gap in the mapping of SMA.

Read Full Report: http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html

There is currently no treatment available for spinal muscular atrophy. Most options available only target the symptoms and not the clinical problem. At the same time, the pipeline for spinal muscular atrophy is fairly dry except for the presence of a few advanced drugs.

North America Scores Highest on SMA Treatment Market Attractiveness

Taking several factors including regulation policies, drug pricing, competitive intensity, and population, it can be said that North America leads in most sub-segments. Researchers and manufacturers concerned with the spinal muscular atrophy are therefore looking to the advanced healthcare infrastructure of North America and Europe.

The North America demand for spinal muscular atrophy treatments largely stems from the U.S. This region shows a higher diagnosis rate of spinal muscular atrophy. It also holds a high amount of government incentives that are given for the development of orphan drugs. The high price of spinal muscular atrophy treatment can be mitigated by the availability of feasible reimbursement policies. Additionally, a large portion of the pharmaceutical industry policies are in favor of this market.

Interpret a Competitive outlook Analysis Report with PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7187

Orphan Drugs to Get Greater Government Incentives

With the U.S. and Europe already having distinguished spinal muscular atrophy as an orphan drug, the government incentives for this category are expected to increase accordingly. Governments are trying to encourage research and development organizations for spinal muscular atrophy to expedite the process of drug development and drug discovery.

Most of the pipeline drugs for spinal muscular atrophy are given several economic advantages such as the clinical research tax credit, a priority new drug application review. This applies especially to the pipeline drugs being developed in the U.S. Similar benefits are also being given to SMA drug developers in Europe. In 2015, only one drug had cleared through to the third phase of clinical and can be expected to enter the market in 2018.

The key players included in the spinal muscular atrophy pipeline assessment are AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche AG, Novartis AG, and Ionis Pharmaceuticals, Inc. The key pipeline drugs for spinal muscular atrophy currently include Olesoxime (TRO19622), LMI070, RO6885247, RG3039, scAAV9.CB.SMN, CK-2127107, and ISIS-SMNRx.

Microbiology Culture Market to Reach US$7.59 bn by 2023 due to Increasing Life Science Research Funding Globally

The soaring demand for antibiotics, on account of the alarming rise in the prevalence of various infections and food-borne diseases, has provided a significant thrust to microbiology culture practices across the world over the last few years. According to the Centers for Disease Control and Prevention (CDC), in the U.S. alone, a total of 23.6 million cases of infectious and parasitic diseases were reported in 2010. Since microbiology culture is an efficient diagnosis method to detect the cause of a number of infectious diseases, its application in the production of antibiotic drugs is witnessing a remarkable rise, worldwide.

The consumption of antibiotics is also experiencing a sturdy growth in the BRICS nation. A 2014 report by Lancet Infectious Diseases Commission stated that the consumption of antibiotic drugs increased globally by 36% from 2000 to 2010, wherein BRICS countries accounted for a share of 76% of this growth. All these factors, together, point towards an opportunity-rich future for the worldwide market for microbiology culture over the coming years.

Read Full Report: http://www.transparencymarketresearch.com/microbiology-culture-market.html

The global market is projected to witness an increase in its opportunity from US$4.5 bn in 2014 to US$7.5 bn in 2023, expanding at a CAGR of 5.90% during the period from 2015 to 2023. The advent of food microbiology, the rise in concerns over food safety, and the increase in the government funding in life science research are some of the other factors expected to drive the global microbiology culture market in the near future.

North America to Retain Dominance in Terms of Revenue

On the basis of region, the global microbiology culture market is segmented into Asia Pacific, Europe, North America, Latin America, the Middle East, and the Rest of the World. North America emerged as the leading regional market in 2014 with a revenue of US$1.6 bn. The presence of a large pool of biopharmaceutical firms and research institutes played a significant role in driving the market for microbiology culture in North America.

Analysts expect this region to retain its lead over the forecast period. However, Asia Pacific is likely to present the most promising opportunities and register the fastest CAGR of 6.80% from 2015 to 2023. The unmet medical needs of people, coupled with the growing prevalence of infectious diseases, the surge in the healthcare expenditure, the rising focus on food safety, and the increasing demand for antibiotics, are likely to provide an opportunity-rich market for participants in the near future.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3232

Complex Media to Remain Most-preferred Culture Media

Complex media, special media, simple media, and synthetic media are the main culture media utilized in microbial culture. Among these, complex media emerged as the most preferred media for microbiology culture in 2014 and was closely followed by special media. As per estimations, complex media will remain the preferred culture media throughout the forecast period as it caters to a wide range of requirements important for the cultivation of nutritionally complex or kinds of unknown bacteria.

The global market for microbiology culture is led by Sigma-Aldrich Co. LLC, Merck Millipore, Thermo Fisher Scientific Inc., and Becton, Dickinson and Co. In 2014, these four players collectively accounted for a share of more than 50% in the overall market. Some of the other prominent players are BioMérieux SA, Bio-Rad Laboratories, Hi-Media Laboratories Pvt. Ltd., Eiken Chemical Co. Ltd., Scharlab S.L., and Neogen Corp.

Adoption of Healthcare Mobility Solutions to Consistently Rise Across the Globe

The rising use of mobile devices and integration of IT technologies in the healthcare industry has laid the foundation for global healthcare mobility solutions market. Healthcare mobility solutions refer to a wide range of software and hardware products that enable the transformation of conventional healthcare processes into automated and knowledge- and information-driven processes. Mobility solutions can make patient care more effective by reducing response time, enhancing workflow efficiency, reducing paper work and chances of erroneous manual recoding of essential health-related data, and reducing the overall healthcare costs and risks. From the point of view of healthcare providers, mobility solutions also help to increase patient throughput, make data organization and management easier as compared to manual records, and enable informed clinical decision-making through real-time access to patient information.

In the past few years, the global healthcare Industry has consistently increased the adoption of enterprise mobility. Much of the healthcare data earlier conveyed through papers have now been turned into electronic records, including test results, healthcare records, consultation notes, diagnoses, etc. This shift from manual data recording and management to electronically stored data and instant forms of data transfer has significantly increased the speed and efficiency of diagnosis and treatment, ultimately leveraging patient satisfaction. With the evolution of electronic communication, mobile devices such as smartphones, tablets, etc., are becoming the preferred tools for patients and healthcare providers as well for convenient communication, anywhere and anytime.

Increased Accessibility to Mobile Devices and the Internet Propels Market

A research undertaken by Alego Health, a U.S.-based healthcare IT services and solutions provider, over 72% nurses and 62% doctors in the U.S. were using smartphones and tablet computers in healthcare settings in 2012. The study also states that nearly 247 mn people in the U.S. in the same year downloaded mobile healthcare apps for personal use. By that year, over 40,000 healthcare mobile apps were available in the market, the number of which has consistently increased ever since.

The high rate of adoption of mobile devices in healthcare facilities, the unprecedented pace at which technological advancements are taking place in the field of mobile connectivity, and the improved network of high-speed Internet across the globe are the key factors propelling the healthcare mobility solutions market.

Healthcare Service Providers Account for Largest Share of Market

A report published by Transparency Market Research on the global market for healthcare mobility solution states that the market will expand at an exceptional 25.5% CAGR between 2015 and 2023. As a result, the market, which had a valuation of US$20.13 bn in 2014, is projected to rise to a valuation of US$148.66 bn by 2023.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4773

The healthcare mobility solutions market serves three major groups of individuals: patients, payers, and healthcare providers. For the patients, the market serves through mobile healthcare apps that allow patients to avail services such as electronic access to self healthcare records, lab results, apply for medical reimbursements, and others. For healthcare providers, healthcare mobility solutions help manage and organize healthcare data and streamline a number of processes in the healthcare a lot more efficiently than manual processes.

Payers, which comprises medical insurance companies or any third party taking care of the healthcare costs of a patient, can make fair use of the transparency provided by healthcare mobility solutions in terms of the actual costs incurred for a healthcare service availed by a patient (the client of the payer, in this case). Currently, it is the segment of healthcare service providers that accounts for the largest share of the global market, which is an estimated 45% in 2014, followed by the patients’ segment. On a global front, North America is the current leader of the market, followed by Europe and Asia Pacific.

New Trends of Parenteral Nutrition Market with Worldwide Industry Analysis to 2023

Parenteral nutrition (PN) is indicated for the patients unable to take sufficient required nutrition via gastrointestinal track for prolonged period. Additionally, PN is necessary when patient cannot be sustained with oral or enteral intake of nutrition supplements. The market for parenteral nutrition is witnessing positive growth majorly due to rising incidence of chronic diseases such as cancer, diabetes and others globally. Additionally, significant increase in cases of preterm babies coupled with malnourished population in developing regions also act as a potential driver for the growth of the market. For example, according to the World Health Organization (WHO), under-nourishment accounts for more than 11% of the global burden of disease and is considered to be the number one risk to health and wellbeing worldwide. The organization also stated that malnutrition contributes around one third of all child deaths globally every year. Other driving factors such as rising approval of novel parenteral nutrition formulations and aging population further boosted the growth of the market to some extent. However, side effects such as catheter infections, refeeding syndrome, particulate contamination and liver dysfunction with parenterally administration of nutrition hampers the global market growth. The global parenteral nutrition market was valued at US$ 4.1 Bn in 2014 and is estimated to reach a market value of US$ 6.9 Bn in 2023 expanding at a CAGR of 5.7% from 2015 to 2023.

The market of global parenteral nutrition market is categorized into major product types such as carbohydrates, parenteral lipid emulsion, single dose amino acid solution, trace elements, and vitamins and minerals. Single dose amino acid solutions accounted for the largest market, capturing almost 34.1% share of total parenteral nutrition market in 2014. Growing product approvals coupled with increasing utilization of single dose amino acid solutions by end users drive the market growth in future. However, parenteral lipid emulsion segment is anticipated to grow with the highest CAGR due to potential benefits such as minimal interference with pulmonary hemodynamics and others fuel the uptake of this product, leading to market growth.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3611

Global parenteral nutrition market, by geography is segmented as North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. In 2014, North America dominated the global parenteral nutrition market. Rise in regulatory approval for novel parenteral nutrition coupled with consistent rise in the incidence of chronic diseases in the region stimulated the growth of North America parenteral nutrition market. Europe accounted for the second largest share of the total market in 2014 owing to the favorable growth conditions for pharmaceutical and biotechnology manufacturers due to affordability for branded formulations by consumers. However, Asia Pacific region is estimated to grow with the highest CAGR of 7.3%. Market growth in this region is witnessed due to increasing interest of leading companies such as Baxter, Fresenius and others to establish their presence in Asia Pacific countries such as China and Japan.

Some of the prominent players in the global parenteral nutrition market are Fresenius SE & Co. KGaA, Baxter International, Inc., Grifols S.A., Claris Lifesciences Limited, Sichuan Kelun Pharmaceutical Co., Ltd., Allergan plc (Actavis plc), B. Braun Melsungen AG, Pfizer, Inc. (Hospira, Inc.) and others.

Spinal Muscular Atrophy Market: Business Challenges, Emerging Technologies & Competitive Landscape

A new report, titled “Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023” has been published by Transparency Market Research. The study offers a detailed analysis of the spinal muscular atrophy market, providing insights into the pipeline assessment, major growth drivers, restraints, and potential opportunities. According to the research study, the spinal muscular atrophy phase three candidate ISIS-SMNRx is projected to generate revenue of US$0.47 by the end of 2023 in the U.S.

Spinal muscular atrophy (SMA) is one of the rare neuromuscular disorder that affects certain parts of the nervous system, which controls the muscle movement. In the last few years, there has been an increase in the number of SMA cases across the globe. Spinal muscular atrophy is considered as one of the prominent genetic disorders resulting in mortality among infants. The spinal muscular atrophy market has been classified on the basis of symptoms into type 1, type 2, type 3, and type 4 spinal muscular atrophy. Type 1 SMA is referred as the most severe form that affects infants aged 1 to 6 months. As per the report, around 60% of the overall SMA cases are of type 1, in which infants do not live more than two years. Type 2 SMA is considered moderate, which affects children between 6 and 18 months. Type 3 and type 4 patients mostly have a normal life expectancy.

The research study further discusses the pipeline of the spinal muscular atrophy. Early stage candidates and late stage candidates are the two major segments studied in the report. At present, ISIS-SMNRx by Ionis Pharmaceuticals, Inc. is the only late stage drug candidate present in the spinal muscular atrophy pipeline. Furthermore, three drugs are in phase 2 and three others are in phase 1 in the SMA pipeline. The rising research activities are expected to introduce more drug candidates in the pipeline, driving the overall market in the near future.

The research study gathers information from governments and corporate sources, including the U.S. and Europe clinical trial registries, Centers for Disease Control and Prevention (CDC), company press releases, World Health Organization (WHO), Families of SMA, CureSMA, PubMed, annual reports, and investor presentations. The analysis in the report offers inputs given by industry experts with their expertise in rare disease drug discovery.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187

In the last few years, Europe and the U.S. have witnessed significant increases in the number of diagnosed cases of spinal muscular atrophy. Thus, private organizations and governments are making efforts to create an awareness regarding the disease among the population. Furthermore, the rising confirmed carrier population in these regions are further anticipated to contribution substantially towards the growth of the spinal muscular atrophy market. In addition, the government incentives offered for developing therapeutic alternatives are projected to drive the overall market in the next few years.

Furthermore, the research study offers a detailed analysis of the players operating in the spinal muscular atrophy market. Some of the leading players are Ionis Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., AveXis, Inc., Novartis AG, and Cytokinetics, Inc. The contact information, business strategies, product portfolio, financial status, SWOT analysis, and recent developments have been discussed in the research report. In addition, the potential candidates in clinic trials and pipeline for treatment of spinal muscular atrophy have also been covered in the research report.

Global Hypertrophic Cardiomyopathy Therapeutics Market to reach US$1.4 bn by 2023

The rising prevalence of chronic cardiovascular ailments has spurred the demand for effective therapeutics, thereby driving the global hypertrophic cardiomyopathy (HCM) therapeutics market. In a report titled “Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023,” Transparency Market Research studies in detail the various factors fueling and challenging the global market.

According to the American Heart Association, hypertrophic cardiomyopathy is a common condition that occurs when the muscle cells of the heart enlarge, causing the ventricle walls to thicken. HCM affects both men and women and is a common cause of sudden cardiac arrest in young people. The rising incidence of obstructive and non-obstructive hypertrophic cardiomyopathy is anticipated help the global market maintain a steady, albeit meager CAGR of 1.4% from 2015 to 2023. In 2014, the value of the hypertrophic cardiomyopathy therapeutics market was pegged at US$1.2 bn, which is forecast to increase to US$1.4 bn by 2023.

The global market for hypertrophic cardiomyopathy therapeutics has been studied on two fronts: By drug class and by geography.

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been categorized into calcium channel blockers, anticoagulants, beta adrenergic blocking agents, and antiarrhythmic agents. Although beta adrenergic blocking agents are the first preference for the treatment of obstructive as well as non-obstructive hypertrophic cardiomyopathy, calcium channel blockers form the largest segment in the overall market in terms of revenue. This can be attributed to the fact that the price of the latter blocking agents is much higher than that of the former.

By geography, the global hypertrophic cardiomyopathy therapeutics market comprises, Asia Pacific, North America, Europe, and Rest of the World. North America and Europe dominate the worldwide market, with the U.S. being the largest market for hypertrophic cardiomyopathy therapeutics. Accounting for a share of over 30% in 2014, the country is projected to retain is lead position throughout the forecast period. The hypertrophic cardiomyopathy therapeutics markets in Europe and North America are fueled by the rising prevalence of sedentary lifestyle among the younger population, the availability of modern healthcare infrastructure, and an increased presence of obesity. Growing awareness about hypertrophic cardiomyopathy and the various therapeutics available today has also significantly propelled the hypertrophic cardiomyopathy therapeutics market in these two regions.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

Asia Pacific is predicted to be the fastest expanding market by 2023, fueled primarily by the rapid development in healthcare infrastructure, the increasing prevalence of various chronic diseases, and the growing awareness about various cardiac complications.

The report offers a detailed section on the competitive landscape of the global hypertrophic cardiomyopathy therapeutics market. The strengths, weaknesses, opportunities, and threats of each of the profiled players have also been examined in the report. Some of the promising companies in the hypertrophic cardiomyopathy therapeutics market are Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Merck & Co., Inc., AstraZeneca plc, Concordia Healthcare Corp., Pfizer, Inc., Mylan N.V., Novartis AG, and Sanofi S.A.

Ophthalmic Drugs Market: Business Challenges, Emerging Technologies & Competitive Landscape

A research report, published by Transparency Market Research (TMR), estimates the global ophthalmic drugs market to reach US$21.6 billion by 2018, expanding at a CAGR of 5.2% between 2013 and 2018.The report, titled “Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018”, reveals that the worldwide ophthalmic drugs market stood at US$16 billion in 2012. It also determines the key drivers as well as major restraints of this market.According to the report, the rising prevalence of eye disorders across the world is the main driving force behind the development of this market. Apart from this, increase in the global geriatric population is also propelling the market, as with increasing age, the eyesight starts to diminish in human beings. However, the lack of awareness about various eye-related disorders and dearth of innovative ophthalmic drugs are hampering the global market. In addition to this, patents of many blockbuster drugs are on the verge of expiration, which is expected to make things worse for the market during the forecast period.

Prescription drugs and over the counter (OTC) drugs are the two main types of ophthalmic drugs available in the global market.Based on treatment, dry eye drugs, anti-allergic/anti-inflammatory/anti-infective drugs, retinal drugs, and anti-glaucoma drugs are the key segments of the global ophthalmic drugs market. The anti-glaucoma drugs segment leads the global ophthalmic treatment drugs market and analysts expect this segment to expand at a CAGR of 4.2% over the forecast period.

Regionally, North America dominates the global ophthalmic drugs market and is expected to maintain its dominant position owing to the increasing initiatives to curb blindness and other eye-related disorders among the geriatric population.On the other hand, Asia Pacific is reporting the fastest growth in the market for ophthalmic drugs across the globe on account of the rising incidence of blindness among the geriatric population in this region. This trend is likely to continue over the period from 2013 to 2018. India, China, and several nations in Southeast Asia are the key consumers of ophthalmic drugs and rising demand from these countries is fuelling the Asia Pacific ophthalmic drugs market.The global market for ophthalmic drugs is led by Novartis, which held around 24% of the overall market in 2012. Other major players operating in this market are Allergan, Santen, Merck & Co., Bayer, Roche, Senju, Valeant, Regeneron, and Pfizer, as per the market report.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1769

The report covers all the critical aspects of the global ophthalmic drugs market and makes significant assessments on overall performance of this market at present as well as historically. The main objective of this report is to help market participants understand the trends and movements of this market and empower them to make crucial strategies for significant development of their businesses.

Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market

There are a few key causes of a fatty liver, one of which is non-alcoholic fatty liver disease. It occurs when excessive alcohol consumption causes large deposits of fat in the liver. It is one of the most commonly linked diseases to alcoholism and also one of the most commonly found liver disorders in developed economies. Non-alcoholic fatty liver disease (NAFLD) is caused by reasons linked to metabolic issues and insulin resistance. Obesity is another factor that can significantly increase the chances of contracting NAFLD. According to the National Health and Nutrition Examination Survey, the rate of NAFLD in the U.S. within 2011 and 2012 was nearly 30%. In cases where NAFLD was not detected in time and reached higher levels of complications, non-alcoholic steatohepatitis (NASH) can occur. It is the most extreme form of non-alcoholic fatty liver disease and is a direct causative factor for liver cirrhosis. NAFLD by itself can be treated successfully if detected in time. NASH, on the other hand, needs special care.

The global non-alcoholic steatohepatitis therapeutics market is expected to reach US$20.2 bn by the end of 2025. It is expanding at a CAGR of 10.70% between 2015 and 2025. The key players in this market that are expected to play a major role in the market’s immediate future include Tobira Therapeutics, Inc., Conatus Pharmaceuticals, Immuron Ltd., Zydus Cadila, Gilead Sciences, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., and Astazeneca Plc.

Elafibranor Propels Global NASH Market

The major segments of the market by drug type include Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and potential drug candidates in phase III. Elafibranor is expected to lead the market in the near future by being the largest and fastest growing segment of the global non-alcoholic steatohepatitis therapeutics market. Elafibranor is currently the most advanced and most effective drug in this market and is expected to exhibit the highest CAGR of all the various drug types.

There are no treatments that are specifically used for non-alcoholic steatohepatitis. Apart from the various drugs used for the treatment of fatty liver, doctors often suggest the patient to start losing weight if they are overweight. Other suggestions given include completely avoiding alcohol, consuming a balanced diet, and increasing physical activity.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

NASH and NAFLD Linked to Obesity

Medical records are pointing to an increasing prevalence of NAFLD and NASH across the world. However, these issues are more common in developed economies such as North America. This is due to the larger percentage of the obese population in the total population in developed regions than others. The global non-alcoholic steatohepatitis therapeutics market is, therefore, developing at a higher rate in countries such as the U.S., owing to the higher demand for NASH and NAFLD treatment options. The healthcare industry in these regions is taking fatty liver complications a lot more seriously. In the recent past, the number of obese adults and children in the U.S. have doubled and tripled, respectively. This is a major issue, as obese patients who suffer from NFALD or NASH are also likely to suffer from high blood cholesterol and diabetes.

Apart from obesity, patients of glucose intolerance and dyslipidemia are also prone to suffer from NFALD and NASH. There is no clear link that points to the reason NFALD occurs, but it is currently suggested that insulin resistance has a major role to play in it. In spite of the severity of the disease, patients are largely asymptomatic until complications arise. Therefore, the best preventive measure against NFALD and NASH is to lead a healthy life and moderate alcohol consumption.

How to Invest in Biotherapeutics Cell Line Development Market

There has been a steady rise in the demand for cell lines for the production of recombinant protein therapeutics as the US Food and Drug Administration (FDA) approves an increasing number of these biotherapeutics. While the period of 2006 to 2011 saw an average of 15 novel recombinant protein therapeutics gain approval, 2014 alone had 11 therapeutics gain FDA approval. The rising prevalence of communicable diseases, combined with increase in geriatric population, has driven the global biotherapeutics cell line development market. Moreover, strong initiatives taken by several governments to boost research and development in the field of life sciences have also contributed towards the growth of the biotherapeutics cell line development market.

Steady Growth in Store for Global Biotherapeutics Cell Line Development Market

According to a recent report by Transparency Market Research, the global market for biotherapeutics cell line development is forecast to expand at a steady CAGR of 7.50% from 2015 to 2022, growing from a value of US$56 mn in 2014 to US$99.8 mn in 2022. This growth can be attributed to a number of factors such as rise in vaccine production, development of innovative technologies boosting the scale of cell lines, the surging demand for monoclonal antibodies, and the increasing investments and funding from companies, governments, and research organizations. While the growing geriatric population, low income countries presenting lucrative opportunities, and the increasing risk of communicable diseases and pandemics is projected to fuel the biotherapeutics cell line development market in the coming years, the challenge of developing authentic and stable cell lines is sure to limit its growth.

Asia Pacific Presents Strong Opportunities for Growth

The global biotherapeutics cell line development market is geographically segmented into North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. North America dominates the worldwide market for biotherapeutics cell line development and this region is forecast to retain its lead through 2022, followed by Europe. The North America biotherapeutics cell line development market is fueled by rising prevalence of diseases, strong research and development activities, and rising proportion of geriatric population. Asia Pacific is projected to develop at the fastest pace from 2015 to 2022, driven by growing investments by multinational biopharmaceutical manufacturers.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

By process, the biotherapeutics cell line development market is bifurcated into single cell cloning and transfection and selection. The segment of single cell cloning is further segmented into FACS, manual limited dilution cloning, ClonePix, and others. Analysts at TMR reveal that accounting for a share of 37.40% in 2014, ClonePix emerged as the leader in the overall market. By cell line development option, the market is divided into outsource, in-house, do-it-yourself (DIY), and hybrid. The rising trend of outsourcing is likely to propel the outsource segment to develop at the fastest pace.

Some of the leading companies operating in the biotherapeutics cell line development market are Catalent Inc., Thermo Fisher Scientific Inc., Sigma-Aldrich Co. LLC., ProBioGen AG, EMD Millipore, Boehringer Ingelheim Group, Beckman Coulter, Selexis SA, Beckton Dickinson & Company, CMC Biologics A/S, Sony Biotechnology Inc., Partec (Sysmex Corporation), and Lonza Group Ltd.

Hypertrophic Cardiomyopathy Therapeutics Market: Challenges and Opportunities

Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010 stated that there was no significant gender and age range differences in the prevalence of HCM. Prevalence of HCM is higher among African-Americans compared to other races. The global hypertrophic cardiomyopathy therapeutics market was valued at USD 1,216.3 million in 2014 and is projected to reach USD 1,378.4 million by 2023, expanding at a CAGR of 1.4% during the forecast period.

The global hypertrophic cardiomyopathy therapeutics market has been broadly categorized into drug class and geography. Beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, and anticoagulants together constitute the drugs class segment of the hypertrophic cardiomyopathy therapeutics market. Calcium channel blockers was the largest segment in 2014, although beta adrenergic blocking agents were the first choice for treatment of obstructive and non-obstructive HCM. Price of calcium channel blockers is higher than beta adrenergic blocking agents; hence, in terms of revenue, calcium channel blockers dominated the hypertrophic cardiomyopathy therapeutics market in 2014. A similar trend is expected to continue during the forecast period. Calcium channel blockers are anticipated to expand at a CAGR of 1.8% from 2015 to 2023.

Geographically, the hypertrophic cardiomyopathy therapeutics market has been segmented into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). The market is primarily concentrated in the U.S., followed by Europe. The U.S. was the most attractive market for hypertrophic cardiomyopathy therapeutics in 2014, with more than 30% share of the global market. Europe accounted for the second-largest share of the global market in 2014. In 2014, the U.S. and Europe primarily dominated the hypertrophic cardiomyopathy therapeutics market due to modern healthcare infrastructure, increasing sedentary lifestyle among the youth, and rising obese population. Additionally, high awareness about HCM in developed countries boosts the market growth. North America is expected to continue its dominance during the forecast period. Asia Pacific was the fastest growing markets due to rising disease prevalence, developing healthcare infrastructure, and increasing awareness about cardiac complications in these regions. However, technological advancements in devices such as defibrillators and pacemakers are estimated to hamper market growth. This, in turn, would restrict the uptake of hypertrophic cardiomyopathy drugs. Thus, market leaders are recommended to focus on the development of new drugs or combination drugs that are specifically targeted toward hypertrophic cardiomyopathy in order to gain competitive advantage in the market.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are some of the major companies operating in the global hypertrophic cardiomyopathy therapeutics market.

Global Report on Parenteral Nutrition Market

According to a research report released by Transparency Market Research, the global parenteral nutrition market is experiencing a CAGR of 5.7% within a forecast period ranging from 2015 to 2023. This market is expected to be valued at US$6.9 bn in 2023. As per the data provided by the leading market intelligence firm, the global parenteral nutrition market was recorded at US$4.1 bn in 2014 and is currently influenced by a number of factors. These are the findings of a latest research report, titled “Parenteral Nutrition Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

As stated in the report, the global parenteral nutrition market is currently being driven by a growing count of patients that are suffering from chronic diseases. These include GI disorders, renal disorders and renal failure, Crohn’s disease, ischemic bowel disease, short bowel syndrome, and various types of cancers.

The report cites a study published by the WHO, in which it is stated there were 14 mn new cases of cancer in 2012. Cancer is one of the leading causes of mortality and morbidity across the world, and is expected to continue growing in prevalence. The number of cancer cases are expected to see a sharp increase of 70% between 2025 and 2035, thereby becoming a leading factor pushing for the growth and development of the global parenteral nutrition market.

The report divides the global parenteral nutrition market on the basis of nutrient type, into vitamins and minerals, trace elements, single dose amino acid solutions, parenteral lipid emulsion, and carbohydrates. The leading segment in the market in 2014 was single dose amino acids, owing to the high approval rates of novel amino-acid-based parenteral products. The segment of carbohydrates, which occupied over 23% of the market at the time, is particularly driven by the growing usage of parenteral nutrition for premature babies.

The fastest growth rate is currently attributed to the segment of parenteral lipid emulsion, owing to a rapidly growing demand for this potentially high nutritional drug delivery segment.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3611

The global parenteral nutrition market is also divided based on region, into the major locations of North America, Asia Pacific, Latin America, and the MEA. According to the report, nearly 68% of the market was occupied by North America and Europe in 2014. Both regions showed a growth in the market due to the high rate of chronic disease, the growth in geriatric population, and the rapid approval of new parenteral formulations. On the other hand, Africa and the Middle East showed the lowest revenue and growth rate in the global parenteral nutrition market, owing to lack of adequate healthcare facilities and a shortage of parenteral nutrition products.

The key players in the global parenteral nutrition market, as stated in the report, include Claris LifeSciences Limited, Fresenius SE & Co. KGaA, Baxter International, Inc., Grifols S.A., B. Braun Melsungen AG, and Hospira, Inc.

Non Small Cell Lung Cancer Therapeutics Market - An Emerging Worldwide Industry

Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.” According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023.

The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014. High demand for Avastin in major geographies such as Europe and the U.S. is likely to propel the segment during the forecast period. The angiogenesis inhibitor segment was valued at US$ 1,627.1 Mn in 2014 and is likely to account for US$ 2,020.4 Mn by 2023, expanding at a CAGR of 1.8% from 2015 to 2023.

The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.

AstraZeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company.

Growing Prevalence of Chronic Diseases Drives Patient Engagement Solutions Market

Transparency Market Research has published a new report on the global patient engagement solutions market. As per the report, the global patient engagement solutions market is expected to expand at a 23.0% CAGR from 2015 to 2023. The report, titled ‘Patient Engagement Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,’ states that the market will progress from US$6.66 bn in 2014 to US$34.94 bn by 2023. The introduction of IT in healthcare services and improvements in the quality of healthcare services are some of the factors expected to propel the global patient engagement solutions market in the near future.

Patient engagement solutions offer enhanced healthcare to patients by including electronic devices and advanced IT services in their medical routine. These medical services and solutions assist patients in taking better healthcare-related decisions, thus enabling a healthier life. To deliver enhanced quality healthcare services, patient engagement solutions are supported by healthcare organizations and hospitals. The basic need to use patient engagement solutions is to build a healthy relation between patients and healthcare service providers and promote active participation for self-care.

Since the inclusion of IT in the healthcare industry, the global patient engagement solutions market has gone through many developments. For example, the increasing adoption of electronic healthcare records systems is being seen because of the effective use of IT in healthcare services. Going forward, improved infrastructure is expected to propel the global patient engagement solutions market.

Patient engagement solutions offer many services such as lab reports, medication/appointment reminders, and healthcare tips. With enhanced patient engagement solutions, patients can manage their healthcare expenses in a better way. The global patient engagement solutions market is segmented on the basis of end user, region, and delivery mode. By delivery mode, the global patient engagement solutions market is classified into software as a service (SaaS), application managed services, and self-hosted services. In 2014, the global patient engagement solutions market was dominated by the self-hosted service segment. However, the SaaS segment is predicted to expand at a 23.60% CAGR from 2015 to 2023 owing to the increasing adoption of HCIT services by healthcare service providers and hospitals.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4506

By end user, in 2014, the global market for patient engagement solutions was dominated by the hospitals and providers segment. Pharmaceutical companies and healthcare payers are two of the other end-user segments of patient management solutions. In 2014, the hospitals and providers segment accounted for 42.4% of the global patient engagement solutions market. However, the pharmaceutical companies segment is predicted to expand at a 24.1% CAGR from 2015 to 2023.

The global patient engagement solutions market is geographically spread across regions such as North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. Some of the key companies operating in the global patient engagement solutions market are McKesson Corporation, Medecision, Inc., Emmi Solutions, LLC, GetWellNetwork Inc., Athena Health, Inc., Axial Exchange Inc., Phytel, Inc. (An IBM Company), Allscripts Healthcare Solutions, and Orion Health Ltd.